Growth hormone-releasing hormone (GHRH, Sermorelin) and Growth hormone-releasing peptides (GHRPs)

• Overview: GHRH; GHRPs

  • Hypothalamic growth hormone-releasing hormone (GHRH):  pituitary growth hormone (GH) secretion

  • GHRH belongs to a family of molecules including:

    • Secretin, VIP, gastric inhibitory peptide (GIP), glucagon.

  • Major site of GHRH production: arcuate nucleus hypothalamus.

  • GHRH receptor:

    • G protein-coupled transmembrane receptor

    • Activation :  ­GH gene transcription, ­synthesis and ­GH release (cAMP mediated)

• Chemistry, Pharmacokinetics, and Pharmacodynamics:  GHRH and GHRP

  • Chemistry: GHRH and GHRP

    • Growth hormone-releasing hormone:

      • 44-amino acid peptide leads to GH release stimulation.

      • Activity is expressed in the first 29-amino acids.

      • Growth-hormon releasing hormone (GHRH) is also known as growth-hormone releasing factor (GRF), GHRF, somatoliberin or somatocrinin.

    • Growth hormone-releasing peptides

      • Groups of small, synthetic peptides

      • Stimulate GH secretion (similar to GHRH)

  • Pharmacokinetics: GHRH and GHRP

    • GHRH: Routes of administration:

      • IV

      • Subcutaneous

      • Intranasal

  • Pharmacodynamics: GHRH and GHRP

    • Stimulation: growth hormone secretion only (anterior pituitary)

• Clinical use:  GHRH and GHRP

  • GHRH: evaluation of short children with subnormal GH response to:

    • Insulin-induced hypoglycemia, oral L-DOPA, IV arginine

    • Normal response in this group:  GH deficiency secondary to hypothalamic dysfunction

    • Subnormal response in this group:   pituitary or hypothalamic dysfunction

    • Growth hormone level increase following GHRH:   favorable clinical response to GHRH treatment

•   Toxicity: GHRH and GHRP

  • Facial flushing; injection site discomfort (nasal GHRP-2 appears to be well tolerated).

Primary Reference: Fitzgerald, P.A. and Klonoff, D.C. Hypothalamic and Pituitary Hormones, in Basic and Clinical Pharmacology, (Katzung, B. G., ed) Appleton-Lange, 1998, pp 603-618.

Primary Reference: Biller, Beverly M. K. and Daniels, Gilbert, H. Neuroendocrine Regulation and Diseases of the Anterior Pituitary and Hypothalamus, In Harrison's Principles of Internal Medicine 14th edition, (Isselbacher, K.J., Braunwald, E., Wilson, J.D., Martin, J.B., Fauci, A.S. and Kasper, D.L., eds) McGraw-Hill, Inc (Health Professions Division), 1998, pp 1972-1998

This Web-based pharmacology and disease-based integrated teaching site is based on reference materials, that are believed reliable and consistent with standards accepted at the time of development. Possibility of human error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete. Users should confirm the information contained herein with other sources. This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site. Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals. Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.  Advertisements that appear on this site are not reviewed for content accuracy and it is the responsibility of users of this website to make individual assessments concerning this information.  Medical or other information  thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.